Neoadjuvant Therapy for Organ Preservation in Head and Neck Cancer
- 1 December 2000
- journal article
- clinical trial
- Published by Wiley in The Laryngoscope
- Vol. 110 (12) , 2074-2080
- https://doi.org/10.1097/00005537-200012000-00019
Abstract
We designed two sequential trials of induction chemotherapy followed by definitive radiation in patients with potentially resectable head and neck cancer to determine whether organ preservation is feasible without apparent compromise of survival Study Design Both trials were Phase II studies. Two clinical trials were conducted sequentially at the University of Michigan. Fifty-two patients enrolled in the first study and were treated with a planned three cycles of carboplatin and 5-fluorouracil. Patients who achieved at least 50% reduction in the size of the primary tumor received definitive radiation therapy, to a dose of 6600 to 7380 cGy. Patients with minimal response or progression had immediate salvage surgery. Thirty-seven patients enrolled in the second trial, in which the chemotherapy consisted of carboplatin, 5-fluororuracil, and leukovorin. Responders were treated with accelerated radiation therapy, to a total dose of 7120 cGy delivered in 41 fractions over 5.5 weeks. Toxicity and response were similar in both trials; therefore, the results are reported first separately and then combined for all 89 patients. Tumor sites included: oropharynx, 55 patients; hypopharynx, 34 patients. Eighty-three percent of patients tolerated all three cycles of chemotherapy and toxicity was mild. Response to chemotherapy was: 48% complete response at the primary tumor site, and 34% partial response at the primary tumor site. Initial organ preservation at individual tumor sites was: oropharynx, 58%; hypopharynx, 59%. Median survival was 28 months, and survival at 3 and 5 years was 40% and 24%, respectively. These two regimens were well tolerated, and survival did not appear to be compromised by organ preservation treatment compared with historical controls. This approach warrants further investigation, particularly in those patients for whom surgery could be functionally debilitating.Keywords
This publication has 15 references indexed in Scilit:
- Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.Journal of Clinical Oncology, 1997
- Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III TrialJNCI Journal of the National Cancer Institute, 1996
- Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.Journal of Clinical Oncology, 1994
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991
- Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the southwest oncology groupThe Laryngoscope, 1988
- Cisplatin and Fluorouracil as Neoadjuvant Therapy in Head and Neck Cancer: A Preliminary ReportJAMA Otolaryngology–Head & Neck Surgery, 1987
- Induction Chemotherapy in Advanced Head and Neck Cancer: A Radiation Therapy Oncology Group StudyJAMA Otolaryngology–Head & Neck Surgery, 1987
- Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neckInternational Journal of Radiation Oncology*Biology*Physics, 1985
- A randomized trial of adjuvant chemotherapy in head and neck cancer.Journal of Clinical Oncology, 1985
- Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancerThe American Journal of Surgery, 1982